Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary

Reuters06-25

<a href="https://laohu8.com/S/NVSEF">Novartis AG</a> Acquires Regulus <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Now a Wholly Owned Subsidiary

Novartis AG has successfully completed its acquisition of Regulus Therapeutics Inc., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114700-en) on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2546324800?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546324800","market":"fut","top_or_hot":-1,"title":"Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NVSEF\">Novartis AG</a> Acquires Regulus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Now a Wholly Owned Subsidiary\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novartis AG has successfully completed its acquisition of <a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a>., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114700-en) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-25 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NVSEF\">Novartis AG</a> Acquires Regulus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Now a Wholly Owned Subsidiary\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novartis AG has successfully completed its acquisition of <a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a>., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114700-en) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL6FCkjc:1","article_id":"2546324800","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546324800","pubTimestamp":1750857207,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novartis AG has successfully completed its acquisition of Regulus Therapeutics Inc., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease , a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","RGLS":"Regulus Therapeutics Inc","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"诺华公司收购Regulus Therapeutics，现为全资子公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RGLS":0.9},"content_text":"Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary\n    \n\n        Novartis AG has successfully completed its acquisition of Regulus Therapeutics Inc., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114700-en) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546324800","isCrawlerRequest":true}